title: [Therapeutic intervention alternatives in cancer, using attenuated live bacterial vectors: Salmonella enterica as a carrier of heterologous molecules].
abstract: Salmonella enterica is a facultative anaerobic bacteria, whose ability to colonize antigen-presenting cells (APCs) such as dendritic cells and macrophages, has allowed its successful use as an alive, attenuated bacterial vector for vaccination. Salmonella enterica elicits efficient cellular, humoral and mucosal immune responses, against heterologous antigens including viruses, parasites, other bacterial species and tumor-associated antigens, since it is capable of delivering these antigens to cells of the immune system. The extracellular expression of heterologous antigens on the surface of Salmonella enterica via its type I, III and V secretion systems, and their delivery into infected cells is essential for its stimulation of immune responses against these antigens. Moreover, Salmonella enterica is a promising therapeutic agent against cancer, as demonstrated by reports of pre-clinical and clinical studies indicating that, after systemic administration, Salmonella enterica preferentially localizes in solid tumors and metastases as compared to normal tissues. In this review, we focus on novel prophylactic and therapeutic anti-cancer approaches using Salmonella enterica as a delivery system of heterologous molecules with the aim of inhibiting tumor growth.
authors.affiliation: Unidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México Federico Gómez.
authors.forename: Marco Antonio
authors.initials: MA
authors.lastname: Hernández-Luna
authors.forename: Rosendo
authors.initials: R
authors.lastname: Luria-Pérez
authors.forename: Sara
authors.initials: S
authors.lastname: Huerta-Yépez
mesh_terms: D000818:Animals; D017951:Antigen Presentation; D015478:Antigens, Heterophile / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D058947:Bacterial Secretion Systems; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D016233:Immunotherapy, Active; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000382:microbiology / Q000628:therapy; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D022562:Salmonella Vaccines / Q000627:therapeutic use*; D019779:Salmonella enterica / Q000276:immunology* / Q000502:physiology; D013812:Therapeutics; D062690:Vaccines, Live, Unattenuated; D023041:Xenograft Model Antitumor Assays
chemical_list: D015478:Antigens, Heterophile; D000951:Antigens, Neoplasm; D058947:Bacterial Secretion Systems; D019496:Cancer Vaccines; D016207:Cytokines; D034741:RNA, Small Interfering; D011994:Recombinant Proteins; D022562:Salmonella Vaccines; D062690:Vaccines, Live, Unattenuated